Novel coronavirus vaccine (20 19-nCoVvaccine) is aimed at novel coronavirus. Up to February 25th, 20021year, four COVID-19 vaccines have been conditionally marketed in China, including three inactivated vaccines and one adenovirus vector vaccine.
On June 24th, 2020, China CDC successfully isolated the first novel coronavirus in China. At 20: 00 on March 16, the recombinant COVID-19 vaccine was allowed to start clinical trials. On April 13, China COVID-19 vaccine entered the phase II clinical trial; On the same day, an expert group composed of more than 20 scientists, doctors, funders and manufacturers from all over the world issued a public declaration, promising to work together to accelerate the research and development of vaccines in COVID-19 under the coordination of the World Health Organization. On June 19, the first COVID-19 mRNA vaccine in China was approved for clinical trial. 654381Oct 8, China signed an agreement with the Global Alliance for Vaccine Immunization and formally joined the "COVID-19 Vaccine Implementation Plan". 20021May 7, China COVID-19 vaccine was certified by WHO for emergency use; On June 1, China Kexing COVID-19 vaccine was authorized by WHO for emergency use.
Up to 202 1, 12, 19, 3 1 provinces (autonomous regions and municipalities directly under the central government) and Xinjiang production and construction corps reported 2,684.29 million doses of COVID-19 vaccine. By the end of 20021,12 and 16, the number of children aged 3-10/0 in China has exceeded10.40 billion.
On June 24th, 2020, China CDC successfully isolated the first novel coronavirus in China. The National Pathogenic Microorganism Resource Database released the virus species information and electron microscope photos of the virus (novel coronavirus Wuhan strain 0 1), and also released important authoritative information such as novel coronavirus nucleic acid detection primers and probe sequences. These have laid the foundation for the development of vaccines.
2020122 October, it is reported that the University of Queensland is using a patented technology to rapidly produce a vaccine from novel coronavirus. Keith chapple of the University of Queensland, one of the leaders of the research project, told Xinhua that the research team of the university had obtained the gene sequence of novel coronavirus and was in the initial stage of developing related vaccines. The patented technology named "Molecular Tweezers" developed by the research team of the University of Queensland can increase the stability of the virus protein. The research team tried to use this technology to develop vaccines against Middle East respiratory syndrome coronavirus, Nipah virus, Ebola virus and influenza virus, and achieved very ideal experimental results.